Lisdexamfetamine for binge eating disorder in adults: A systematic review of the efficacy and safety profile for this newly approved indication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

International Journal of Clinical Practice

Volumn 69, Issue 4, 2015, Pages 410-421

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; CENTRAL STIMULANT AGENT; DOPAMINE UPTAKE INHIBITOR; NEUROLEPTIC AGENT;

ADULT; ANXIETY; BINGE EATING DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DECREASED APPETITE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FATIGUE; HEADACHE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; LIKELIHOOD TO BE HELPED OR HARMED; META ANALYSIS (TOPIC); MORNING DOSAGE; NAUSEA; NERVOUSNESS; NUMBER NEEDED TO HARM; NUMBERS NEEDED TO TREAT; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA; BINGE-EATING DISORDER; CLINICAL TRIAL (TOPIC);

ANTIPSYCHOTIC AGENTS; BINGE-EATING DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DOPAMINE UPTAKE INHIBITORS; HUMANS; LISDEXAMFETAMINE DIMESYLATE; NUMBERS NEEDED TO TREAT;

EID: 84925879951     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12639     Document Type: Review

References (29)

1. US Food and Drug Administration. Drug Approval Package. Vyvanse (Lisdexamfetamine Dimesylate) Capsules. Date created March 31, 2007. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/021977s000TOC.cfm (accessed January 18, 2015).
2. US Food and Drug Administration. FDA expands uses of Vyvanse to treat binge-eating disorder. Press Release. January 30, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm (accessed January 31, 2015).
3. Hudson JI, Hiripi E, Pope HG, Kessler RC,. The prevalence and correlates of eating disorder in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348-58.
4. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry 2013; 73: 904-14.
5. Stunkard AJ,. Eating patterns and obesity. Psychiatr Q 1959; 33: 284-95.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Arlington, VA: American Psychiatric Association, 2013.
7. Herman BK, Safikhani S, Hengerer D, et al. The patient experience with DSM-5-defined binge eating disorder: characteristics, barriers to treatment, and implications for primary care physicians. Postgrad Med 2014; 126: 52-63.
8. Wilson GT,. Treatment of binge eating disorder. Psychiatr Clin North Am 2011; 34: 773-83.
9. Vocks S, Tuschen-Caffier B, Pietrowsky R, Rustenbach SJ, Kersting A, Herpertz S,. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord 2010; 43: 205-17.
10. Shire. VYVANSE (lisdexamfetamine dimesylate) capsules, for oral use, CII. Prescribing information. Revised January 2015. http://pi.shirecontent.com/PI/PDFs/Vyvanse-USA-ENG.pdf (accessed January 30, 2015).
11. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 2015 doi: 10.1001/jamapsychiatry.2014.2162. [Epub ahead of print].
12. McElroy S, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Gasior M,. Randomized controlled safety and efficacy trials of lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder. New Research Poster NR8-054, American Psychiatric Association 167th Annual Meeting, New York, NY, May 3-7, 2014.
13. Vickers SP, Heal DJ, Hackett D, Hutson PH,. Effect of lisdexamfetamine in a rat model of binge-eating disorder. Poster 236.03/I11. 43rd Annual Meeting of the Society for Neuroscience, San Diego CA, November 9-13, 2013.
14. Hutson P, Prow M, Rowley H, Cheetham S, Heal D,. Lisdexamfetamine-induced suppression of binge eating in rats is attenuated by the alpha-1 adrenoceptor antagonist, Prazosin. Poster W187. 53rd Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, AZ, December 7-11, 2014.
15. Heal D, Vickers S, Hackett D, Hutson P,. Effect of lisdexamfetamine in a rat model of binge-eating disorder. Poster P.1.g.034. 26th European College of Neuropsychopharmacology Congress, Barcelona, Spain, October 5-9, 2013.
16. Citrome L,. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008; 117: 412-9.
17. Citrome L,. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009; 4: 229-37.
18. Citrome L, Ketter TA,. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-11.
19. Heal DJ, Smith SL, Gosden J, Nutt DJ,. Amphetamine, past and present- A pharmacological and clinical perspective. J Psychopharmacol 2013; 27: 479-96.
20. Krishnan SM, Pennick M, Stark JG,. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig 2008; 28: 745-55.
21. Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B,. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010; 50: 1001-10.
22. Krishnan SM, Stark JG,. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008; 24: 33-40.
23. Krishnan S, Zhang Y,. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008; 48: 293-302.
24. Jasinski DR, Krishnan S,. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009; 23: 419-27.
25. Citrome L, Kantrowitz J,. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. J Expert Rev Neurother 2008; 8: 1079-91.
26. Reas DL, Grilo CM,. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs 2014; 19: 99-142.
27. McElroy SL, Guerdjikova AI, Mori N, O'Melia AM,. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag 2012; 8: 219-41.
28. Reas DL, Grilo CM,. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 2008; 16: 2024-38.
29. Citrome L,. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Int J Clin Pract 2014; 68: 1401-5.